Farrell, K., Fyfe, A., Allan, J., Tait, R. C. and Leach, M. (2016) An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events. Leukemia and Lymphoma, 57(11), pp. 2568-2574. (doi: 10.3109/10428194.2016.1165815) (PMID:27078747)
Full text not currently available from Enlighten.
Abstract
Thrombosis is a well-recognized complication of asparaginase therapy for acute lymphoblastic leukemia (ALL), associated with the depletion of antithrombin (AT). Following a high incidence of thrombotic episodes during induction therapy for ALL in our tertiary referral center, we prospectively instituted a protocol of AT replacement. Forty-five consecutive adolescents and adults with ALL treated with asparaginase-containing phase I induction protocols were included in this observational study. Fifteen received standard therapy with no replacement; the subsequent 30 were managed with the protocol described. One or more low AT levels (<70 iu/dl) were recorded in 76% of patients in the cohort managed using the protocol, resulting them in receiving an AT replacement. There was a significant reduction in the incidence of thrombosis with this strategy (0/30 vs. 5/15, p < 0.001). We suggest that such a strategy should be studied in a prospective randomized sub-study within the context of a national ALL trial.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Tait, Dr Robert and Farrell, Dr Katrina |
Authors: | Farrell, K., Fyfe, A., Allan, J., Tait, R. C., and Leach, M. |
College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
Journal Name: | Leukemia and Lymphoma |
Publisher: | Taylor & Francis |
ISSN: | 1042-8194 |
ISSN (Online): | 1029-2403 |
Published Online: | 14 April 2016 |
University Staff: Request a correction | Enlighten Editors: Update this record